Luis E Aguirre, Somedeb Ball, Akriti Jain, Najla Al Ali, David A Sallman, Andrew Kuykendall, Kendra Sweet, Jeffrey E Lancet, Eric Padron, Rami S Komrokji
{"title":"Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression.","authors":"Luis E Aguirre, Somedeb Ball, Akriti Jain, Najla Al Ali, David A Sallman, Andrew Kuykendall, Kendra Sweet, Jeffrey E Lancet, Eric Padron, Rami S Komrokji","doi":"10.1016/j.clml.2025.03.016","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic disorder characterized by features of myeloproliferation and myelodysplasia. Various prognostic models incorporate clinical, cytogenetic, and molecular factors to assess risk and guide treatment decisions. However, there has been limited exploration of a subset of patients exhibiting more indolent disease behavior. Due to the significant heterogeneity in disease biology, clonal architecture, clinical presentation, and outcomes, identifying key markers is essential for predicting which patients may present with indolent disease and for recognizing those at greater risk of progression who may require early intervention.</p><p><strong>Patients and methods: </strong>We analyzed baseline clinical and molecular parameters in 656 CMML patients, stratifying them into 2 groups: those observed for ≥ 3 years (indolent CMML) and those needing treatment within that period.</p><p><strong>Results: </strong>14% of CMML patients exhibited indolent disease, correlating with superior outcomes (mOS: 78.5 months vs. 25 months in nonindolent cases). Indolent disease was associated with higher hemoglobin and platelet counts, JAK2 mutations, and fewer cytopenias. In contrast, features indicating the need for earlier treatment included leukocytosis, elevated lymphocyte/monocyte counts, higher percentage of circulating immature cells/blasts, increased marrow cellularity/blasts, and NRAS, ASXL1, and RUNX1 mutations. Changes in the M:E ratio, the presence of abnormally localized immature precursors (ALIP) and gain of mutations reflecting clonal evolution indicated clinical decline and need for timely treatment initiation.</p><p><strong>Conclusion: </strong>A small proportion of CMML patients exhibit indolent features linked to better outcomes, contrasting with markers indicating earlier treatment initiation, which are associated with increased risk of progression; recognizing these markers aids in predicting disease aggressiveness.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clml.2025.03.016","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic disorder characterized by features of myeloproliferation and myelodysplasia. Various prognostic models incorporate clinical, cytogenetic, and molecular factors to assess risk and guide treatment decisions. However, there has been limited exploration of a subset of patients exhibiting more indolent disease behavior. Due to the significant heterogeneity in disease biology, clonal architecture, clinical presentation, and outcomes, identifying key markers is essential for predicting which patients may present with indolent disease and for recognizing those at greater risk of progression who may require early intervention.
Patients and methods: We analyzed baseline clinical and molecular parameters in 656 CMML patients, stratifying them into 2 groups: those observed for ≥ 3 years (indolent CMML) and those needing treatment within that period.
Results: 14% of CMML patients exhibited indolent disease, correlating with superior outcomes (mOS: 78.5 months vs. 25 months in nonindolent cases). Indolent disease was associated with higher hemoglobin and platelet counts, JAK2 mutations, and fewer cytopenias. In contrast, features indicating the need for earlier treatment included leukocytosis, elevated lymphocyte/monocyte counts, higher percentage of circulating immature cells/blasts, increased marrow cellularity/blasts, and NRAS, ASXL1, and RUNX1 mutations. Changes in the M:E ratio, the presence of abnormally localized immature precursors (ALIP) and gain of mutations reflecting clonal evolution indicated clinical decline and need for timely treatment initiation.
Conclusion: A small proportion of CMML patients exhibit indolent features linked to better outcomes, contrasting with markers indicating earlier treatment initiation, which are associated with increased risk of progression; recognizing these markers aids in predicting disease aggressiveness.
期刊介绍：
Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
